Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...

Wedbush reissued their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently ...

Dianthus Therapeutics ( NASDAQ:DNTH ) Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened by... Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. These ...

On Wednesday, Stifel analyst Alex Thompson reaffirmed a Buy rating on Dianthus Therapeutics (NASDAQ:DNTH) with a steady price target of $52.00. The endorsement follows the company’s fourth-quarter ...